• Mashup Score: 1

    Coronary artery disease (CAD) is a common co-morbidity in people with HIV (PWH) and impaired coronary endothelial function (CEF) plays a central role in the pathogenesis of CAD. Age-related impaired CEF among PWH, however, is not well characterized. We investigated the association between CEF and age in males and females with and without HIV using 3T magnetic resonance imaging. We measured the changes in coronary cross-sectional area (CSA) and coronary blood flow during isometric handgrip exercise, an established endothelial-dependent stressor with smaller increases in CSA and coronary blood flow indicative of impaired CEF. We included 106 PWH and 82 HIV-negative individuals. Differences in demographic and clinical characteristics between PWH and HIV-negative individuals were explored using Pearson’s chi-squared test for categorical variables and Welch’s t-test for continuous variables. Linear regression models were used to examine the association between CEF and age. CEF was significa

    Tweet Tweets with this article
    • Coronary artery endothelial function and aging in people with HIV & HIV-negative individuals | American Journal of Physiology-Heart & Circulatory Physiology ⁦@CiccaroneCenter⁩ ⁦@hopkinsheart⁩ ⁦@HopkinsMedicine⁩ ⁦@TLeucker⁩ https://t.co/oXYLwFhKBa

  • Mashup Score: 1

    The treatment of dyslipidemia continues to be a dynamic and controversial topic. Even the most appropriate therapeutic range for lipid levels-including that of triglycerides and low-density lipoprotein cholesterol-remain actively debated. Furthermore, with ever-increasing options and available treat …

    Tweet Tweets with this article
    • If you want to learn more about lipids and dyslipidemia in general, see our review Contemporary Management of Dyslipidemia below. Thanks to Drs. @TLeucker, @maciejbanach, @SethShayMartin, Jones, and Toth for the mentorship! https://t.co/g5GWfegQ6G

  • Mashup Score: 4

    The treatment of dyslipidemia continues to be a dynamic and controversial topic. Even the most appropriate therapeutic range for lipid levels—including that of triglycerides and low-density lipoprotein cholesterol—remain actively debated. Furthermore, with ever-increasing options and available treatment modalities, the management of dyslipidemia has progressed in both depth and complexity. An…

    Tweet Tweets with this article
    • Extremely excited to share our piece! A whirlwind review of lipid management and #cvprev, hope it provides some help to others! Huge amount of work work here, thanks to Drs. Toth, @SethShayMartin @TLeucker @maciejbanach and Jones for the support https://t.co/vSepmvXcUE

  • Mashup Score: 6

    LoDoCo2 Trial: Colchicine in Patients with Chronic Coronary Disease is discussed as part of the CardioNerds #CardsJC twitter journal club

    Tweet Tweets with this article
    • Join us tonight for #CardsJC to discuss LoDoCo2💊 w/ FITs: @OranefoJustice & @AlizaHussainMD & Experts: @a_l_bailey @AllanLKleinMD1 @TLeucker @DrMarthaGulati @SethShayMartin @NehalMehtaMD @ErinMichos @seamuswhelton 🔗Summary & Visual Abstract: https://t.co/wOkqwOuUyr https://t.co/TC4upfKI4n https://t.co/Yz1pPqyidi

  • Mashup Score: 1

    Cardiology Today | Significant therapeutic advancements have been achieved in the management of dyslipidemia. The ability to decrease LDL to previously unattainable levels, owing largely to the development of PCSK9 monoclonal antibodies, has illuminated two important lessons. No. 1, when it comes to LDL, data support a “lower is better” paradigm, with outcomes from FOURIER and ODYSSEY OUTCOMES…

    Tweet Tweets with this article
    • A team from @CiccaroneCenter wrote about novel therapies to know for ASCVD prevention in 2021 and beyond for our April issue: https://t.co/zcnxCjvT0h #Cardiotwitter #Cardiology @hopkinsheart @HopkinsMedicine @SethShayMartin @rblument1 @mchilazi @GarimaVSharmaMD @TLeucker

  • Mashup Score: 0

    Significant therapeutic advancements have been achieved in the management of dyslipidemia. The ability to decrease LDL to previously unattainable levels, owing largely to the development of PCSK9 monoclonal antibodies, has illuminated two important lessons. No. 1, when it comes to LDL, data support a “lower is better” paradigm, with outcomes from FOURIER and ODYSSEY OUTCOMES showing

    Tweet Tweets with this article
    • ICYMI: "Data support a 'lower is better' paradigm, with outcomes from FOURIER and ODYSSEY OUTCOMES showing progressive [ASCVD] event reduction even at LDL levels well below 30 mg/dL." @SethShayMartin @rblument1 @TLeucker @GarimaVSharmaMD @mchilazi https://t.co/DfCL67Zg3I